

| Drug common name | TIGILANOL TIGLATE |
| INN | tigilanol tiglate |
| Description | Tigilanol tiglate (USAN; ), sold under the brand name Stelfonta is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog's skin (subcutaneous), in particular areas of a dog's leg. Stelfonta is injected directly into the MCT (intratumoral injection). Stelfonta works by activating a protein that spreads throughout the treated tumor, which disintegrates tumor cells.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C/C=C(\C)C(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)[C@H](O)[C@@]3(CO)O[C@H]3[C@H]2[C@@H]2C(C)(C)[C@]12OC(=O)[C@@H](C)CC |
| PDB | — |
| CAS-ID | 943001-56-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989916 |
| ChEBI ID | — |
| PubChem CID | 23627739 |
| DrugBank | — |
| UNII ID | R1ZJT87990 (ChemIDplus, GSRS) |
